Literature DB >> 32590326

Pulmonary surfactant itself must be a strong defender against SARS-CoV-2.

Hideyuki Takano1.   

Abstract

Pulmonary surfactant is considered to be one of the soaps. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the other enveloped viruses become very weak against surfactant. The SARS virus binds to angiotensin-converting enzyme (ACE2) receptor and causes pneumonia. In the lung, the ACE2 receptor sits on the top of lung cells known as alveolar epithelial type II (AE2) cells. These cells play an important role in producing surfactant. Pulmonary surfactant is believed to regulate the alveolar surface tension in mammalian lungs. To our knowledge, AE2 cells are believed to act as immunoregulatory cells; however, pulmonary surfactant itself has not been believed to act as a defender against the enveloped viruses. This study hypothesises that pulmonary surfactant may be a strong defender of enveloped viruses. Therefore, old coronaviruses merely cause pneumonia. On the contrary, new SARS-CoV-2 can suppress the production of surfactant that binds to the ACE2 of AE2 cells. The coronavirus can survive in the lung tissue because of the exhaustion of pulmonary surfactant.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ACE2; Alveolar epithelial type II cell; Pulmonary surfactant; SARS-CoV-2

Year:  2020        PMID: 32590326     DOI: 10.1016/j.mehy.2020.110020

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  10 in total

Review 1.  Alveolar type II cells and pulmonary surfactant in COVID-19 era.

Authors:  A Calkovska; M Kolomaznik; V Calkovsky
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

Review 2.  Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components.

Authors:  Dan Li; Xianzheng Wang; Yingzhao Liao; Shouchuan Wang; Jinjun Shan; Jianjian Ji
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

Review 3.  Imaging of COVID-19: An update of current evidences.

Authors:  Shingo Kato; Yoshinobu Ishiwata; Ryo Aoki; Tae Iwasawa; Eri Hagiwara; Takashi Ogura; Daisuke Utsunomiya
Journal:  Diagn Interv Imaging       Date:  2021-05-25       Impact factor: 7.242

4.  Breath-Synchronized Nebulized Surfactant in a Porcine Model of Acute Respiratory Distress Syndrome.

Authors:  Robert M DiBlasi; Masaki Kajimoto; Jonathan A Poli; Gail Deutsch; Juergen Pfeiffer; Joseph Zimmerman; David N Crotwell; Patrik Malone; James B Fink; Coral Ringer; Rajesh Uthamanthil; Dolena Ledee; Michael A Portman
Journal:  Crit Care Explor       Date:  2021-02-15

Review 5.  Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19.

Authors:  Suzy Huijghebaert; Levi Hoste; Guido Vanham
Journal:  Eur J Clin Pharmacol       Date:  2021-03-27       Impact factor: 2.953

6.  Graphene Sheets with Defined Dual Functionalities for the Strong SARS-CoV-2 Interactions.

Authors:  Ievgen S Donskyi; Chuanxiong Nie; Kai Ludwig; Jakob Trimpert; Rameez Ahmed; Elisa Quaas; Katharina Achazi; Jörg Radnik; Mohsen Adeli; Rainer Haag; Klaus Osterrieder
Journal:  Small       Date:  2021-02-02       Impact factor: 13.281

Review 7.  The Role of Pulmonary Surfactants in the Treatment of Acute Respiratory Distress Syndrome in COVID-19.

Authors:  Shengguang Wang; Zhen Li; Xinyu Wang; Shiming Zhang; Peng Gao; Zuorong Shi
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

Review 8.  Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection.

Authors:  Maryam Amini Pouya; Seyyedeh Maryam Afshani; Armin Salek Maghsoudi; Shokoufeh Hassani; Kayvan Mirnia
Journal:  Daru       Date:  2020-07-30       Impact factor: 3.117

9.  Diesel Particulate Matter 2.5 Induces Epithelial-to-Mesenchymal Transition and Upregulation of SARS-CoV-2 Receptor during Human Pluripotent Stem Cell-Derived Alveolar Organoid Development.

Authors:  Jung-Hyun Kim; Jeeyoung Kim; Woo Jin Kim; Yung Hyun Choi; Se-Ran Yang; Seok-Ho Hong
Journal:  Int J Environ Res Public Health       Date:  2020-11-13       Impact factor: 3.390

10.  ACE2 Promotes the Synthesis of Pulmonary Surfactant to Improve AT II Cell Injury via SIRT1/eNOS Pathway.

Authors:  Hailing Xu; Jianguang Xiao
Journal:  Comput Math Methods Med       Date:  2021-08-21       Impact factor: 2.238

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.